Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Completed MK-7962-007 (CADENCE) (Visit 9 and end of treatment [EOT] visit) without discontinuing study intervention and is able to safely enroll into MK-7962-007 (HARMONIZE)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has a diagnosis of pulmonary hypertension (PH) in world health organization (WHO)Group 1, WHO Group 3, WHO Group 4, or WHO Group 5

• Has had a study intervention interruption

• Is pregnant or breastfeeding

• Has chronic liver disease with severe hepatic impairment and/or cirrhosis (eg,hepatic encephalopathy)

• Anticipation of more than 1 valve replacement or repair (mechanical orbiomechanical) and/or have undergone more than 1 valve replacement or repair

• Has severe tricuspid regurgitation due to primary valvular disease (eg, fromendocarditis, carcinoid, or mechanical destruction)

• Anticipated or undergone heart transplant or ventricular assist device implantation

• Has had prior exposure to luspatercept